Business Context and Reporting Period
This Form 8-K is filed by Cerulean Pharma Inc. (not Dare Bioscience, Inc.) on May 19, 2017. The report addresses a regulatory notice received from the NASDAQ Stock Market regarding the company's compliance with listing standards based on its financial position as of March 31, 2017.
Key Financial Metrics
- Stockholders' Equity: $7,741,000 (as of March 31, 2017).
- Compliance Threshold: $10,000,000 (Required minimum under NASDAQ Listing Rule 5450(b)(1)(A)).
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide a clear value for these specific metrics.
Material Changes and Listing Status
The company received written notification from NASDAQ indicating non-compliance with the minimum stockholders' equity requirement. Consequently, NASDAQ is reviewing the company's eligibility for continued listing on the NASDAQ Global Market. The company is currently below the required equity threshold by approximately $2.26 million.
Outlook, Risks, and Management Commentary
Management must take one of two actions by July 3, 2017:
- Submit a specific plan to achieve and sustain compliance with NASDAQ Global Market listing requirements, including a timeframe for completion.
- Apply to transfer the company's securities to the NASDAQ Capital Market, subject to meeting that tier's continued listing requirements.
Risks: If a compliance plan is submitted and deemed insufficient by NASDAQ, the company faces delisting. The company retains the right to appeal such a determination to a NASDAQ Listing Qualifications Panel.
Investor Verification Checklist
- Verify the company's current stockholders' equity and any capital raise activities since March 31, 2017.
- Confirm whether the company has submitted a compliance plan or applied for a transfer to the NASDAQ Capital Market by the July 3, 2017 deadline.
- Monitor subsequent filings for any NASDAQ determination regarding delisting or approval of the compliance plan.
- Review the company's cash burn rate and liquidity position to assess the feasibility of meeting equity requirements.